Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. ICNB provides rapid and precise incision analgesia in the early postoperative period, effectively blocking the transmission of peripheral nociceptive stimuli to the central nervous system. tegileridine PCIA, on the other hand, enhances the function of the endogenous descending pain suppression system through its central G protein pathway activation, covering the pain period after the effect of ICNB wears off and components such as visceral referred pain. At the same time, it can effectively reduce side effects such as respiratory depression and nausea/vomiting, thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Inclusion Criteria:

• Age range: 18 to 75 years old;
• Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
• ASA classification levels I-III;
• BMI 18 ~ 30 kg/m2。
• Voluntarily participate and sign an informed consent form.

Exclusion Criteria:

• Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
• Pregnant or lactating women;
• Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
• Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
• Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
• Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).

Immediately followingpublication. No end date.

Anyone who wishes to access the data.